search
Back to results

MR Imaging Selection for Endovascular Treatment in Acute Ischemic Stroke at 6 to 24 Hours (MIELS)

Primary Purpose

Endovascular Thrombectomy

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Endovascular therapy
Drug
Sponsored by
Tianjin Huanhu Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Endovascular Thrombectomy focused on measuring select patients, endovascular thrombectomy, magnetic resonance imaging, CT/MR perfusion, FVH-DWI mismatch

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients over 18 years of old; Patients with acute anterior circulation ischemic stroke 6-24h after onset and NIHSS score ≥6 and RACE score ≥5 score at 6-24 hours of onset; No intracranial hemorrhage confirmed by cranial CT and CT ASPECTS score ≥ 6; The Modified Rankin Scale (mRS) before the onset of the disease was 0-2; All patients' legal representatives have signed the informed consent form; Pre-survival period 6 months or more. Exclusion Criteria: 1. Active hemorrhage or preexisting tendency to hemorrhage CT shows hypointense areas exceeding 1/3 of the middle cerebral artery supply area, with significant midline structural displacement of cerebral edema Rapid neurological improvement, NIHSS score less than 6, or evidence of spontaneous revascularization Signs and symptoms typical of posterior circulation stroke, such as vertigo, nystagmus, choking, swallowing disorder, ataxia, and gaze to the affected side A stroke attack with epilepsy that prevents an accurate NIHSS score from being obtained. A platelet count of less than 100 x 10^9 /L Hereditary or acquired bleeding tendency, coagulation factor deficiency, recent anticoagulant medication (INR>3 or PPT more than 3 times normal) Presence of signs of cardiac, hepatic or renal failure Baseline blood glucose <50mg/dL (2.78mmol) or >400mg/dL (22.20mmol) Uncontrolled hypertension (SBP >185mmHg; DBP >110mmHg) Expected survival less than 90 days. Pregnancy. Chronic obstructive pulmonary disease, inflammation of the lungs, pleural effusion, ARDS, irregular breathing and other pulmonary diseases requiring emergency treatment. Patients with unstable vital signs (heart rate ≤ 50bpm or ≥ 120bpm, oxygen saturation less than ≤ 90%. R ≥ 30bpm or ≤ 10bpm. Patients who are unable to complete the 90-day follow-up A history of severe allergy to contrast media The presence of any other condition that is not suitable for endovascular treatment.

Sites / Locations

  • TianJinHHRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

MR/CT perfusion group

MRI group

Arm Description

MRI group consisted of patients who underwent DWI, FLAIRE, T1, T2, and MRA sequences.After randomization, the attending physician determined surgical treatment based on the imaging results.

The perfusion sequence was examined by the Control Group, and the F-stroke Stroke software (Brainseal Intelligent Technology) was used for data processing.After randomization, the attending physician determined surgical treatment based on the imaging results.

Outcomes

Primary Outcome Measures

Functionally independent outcome in all enrolled patients
defined as patients with a mRS Score of 0-2 at 90 days (mRS 90d(Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, and 6 death,) of a randomized group of modified intention-to-treat (mITT) patients (defined as patients with acute macrovascular occlusions treated optimally with endovascular or pharmacologic therapy) at 90 days (with an assessment time window of ±14 days) and analyzed for noninferiority.

Secondary Outcome Measures

Modified Rankin scale scores at 90 days
(mRS 90d(Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, and 6 death,) of a randomized group of modified intention-to-treat (mITT) patients (defined as patients with acute macrovascular occlusions treated optimally with endovascular or pharmacologic therapy) at 90 days (with an assessment time window of ±14 days) and analyzed for noninferiority.
Successful reperfusion after endovascular treatment
extended Thrombolysis in Cerebral Infarction (eTICI) score of 2b, 2c or 3.
Recanalization rate
Number of subjects who achieved successful reperfusion/total number of subjects who received endovascular treatment, confirmed by MRA, CTA, or digital subtraction angiography (DSA).
Final infarct volume
change from baseline in the infarct volume as calculated by CBV or DWI.
NIHSS score
scores range from 0 to 42, with higher scores indicating a more severe deficit.
Quality of life assessment at 90 days
European Five Dimensions and Five Levels Scale (EQ-5D-5L) scores (range, -0.39 [worst] to 1.00 [best]); Barthel Index scores at 90 days (range, 0 [severe disability] to 100 [no disability]).
mortality
mortality of all-cause.
symptomatic intracranial hemorrhage
the presence of extravascular blood in the cranium that was associated with an increase in the NIHSS score of ≥4 points or death and was judged to be the predominant cause of neurologic deterioration.
FVH-ASPECT score
FVH-ASPECTS: 0-7, with 0 indicating absence of FVH and 7 suggesting prominent FVH

Full Information

First Posted
October 9, 2022
Last Updated
March 6, 2023
Sponsor
Tianjin Huanhu Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05735301
Brief Title
MR Imaging Selection for Endovascular Treatment in Acute Ischemic Stroke at 6 to 24 Hours
Acronym
MIELS
Official Title
MR Imaging Selection for Endovascular Treatment in Acute Ischemic Stroke at 6 to 24 Hours: A Prospective Multicenter Randomized Clinical Trial of FVH-DWI Mismatch Versus CT/MR Perfusion
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2019 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tianjin Huanhu Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The acute management of stroke patients requires a fast and efficient screening imaging modality. The primary modalities used to select patients for endovascular thrombectomy (EVT) are magnetic resonance imaging (MRI) and CT/MR perfusion. The investigators prospectively assessed MRI and CTP concordance/discordance and correlated the imaging on both with EVT treatment decisions and clinical outcomes to verify the validity of MRI (FVH-DWI mismatch) for the preoperative assessment of EVT in patients with an extended time window (6h to 24h).
Detailed Description
The efficacy and safety of endovascular thrombectomy(EVT) in patients with acute ischemic stroke(AIS) due to anterior circulation large vessel occlusion(LVO) is well established in multiple randomized controlled trials (RCTs) in late (treatment) time windows (6-16hours),and compared with medical therapy, EVT can significantly improve the prognosis. DEFUSE 3(EndovascularTherapy FollowingImagingEvaluationforIschemicStroke3)andDAWN (DWIorCTPAssessmentWithClinicalMismatchintheTriageof Wake-UpandLatePresentingStrokesUndergoing NeurointerventionWithTrevo) reliedonCT-perfusion(CTP) or magneticresonancediffusion(DWI)and/orperfusion(PWI), and utilized automated imaging analysis with Rapid Processing of Perfusion and Diffusion (RAPID; iSchemaView, Menlo Park, CA) software to determine eligibility[2,3,4].Some use cerebral infarction volume, presence or absence of cerebral hemorrhage and bleeding tendency, arterial occlusion location, perfusion parameters (CBV<70 mL; The gold standard for mismatch ratio ≥1.8; mismatch volume >15 ml) toassess patients who were compatible with acute anterior circulation LVO ischemic stroke undergoing arterial thrombectomy. The advantages of using perfusion imaging assessment are the ability to identify DWI-negative cerebral ischaemia, objectively evaluate ischemic semi-dark bands, and identify some cases of overperfusion. However, for most centers, CT OR MRperfusion in the emergency department is limited, or the appropriate analysis software is not available, and even imaging equipment does not support perfusion. As a result, most of the centers use multiparametric MR to screen EVT-eligible LVO patients. In the study of DAWN,researchers use MR and some complicated criterias such as clinical symptom-imaging mismatch, the relationship between age and NIHSS score to select patients who meet 6-24hours with acute anterior circulation LVO, It wasa certain complex way to used in clinical work, and difficult to promoting the application clinically. All the acute ischemic stroke protocols are trying to find a way to balance theoptimal screening assessment of EVT patients (with)and minimal imaging time to facilitate rapid and effective treatment. Fast multiparametric MR sequences typically include DWI, FLAIR, MRA, and gradient echo(GRE) sequences, further reducing the time and versatility of multiparametricMRI scans, requiring more informations to be extracted from fewer sequences. Early researches described that a rounded or serpentine brightening of the parenchyma or cortical surface bordering the subarachnoid space in FLIAR sequence on MRI scan is called fluid attenuation inversion recovery vascular hyperintensity(FVH). In a prospective study, slow blood flow on the FLAIR sequence was associated with cerebral collateral circulation and prognosis [12].At the same time, it has been suggested that FVH in the FLAIR sequence of the MRI scan sequence can indirectly indicate LVO or vascular stenosis, and insufficient collateral circulation leads to FVH and early ischemia [1]. According to our completed retrospective study, FVH-DWI mismatch assessment and perfusion assessment showed good interrater reliability( κ= 0.71,[95% CI, 0.62-0.81]). There is no statistical difference in the rate of good clinical prognosis of patients undergoing EVT based on the two evaluation methods(X2=0.204,P=0.652). It has been found that FVHsign is an indicator of LVO or vascular stenosis, inadequate collateral circulation leading to slow blood flow and early ischaemia. The presence of the FVH sign is not only fairly consistent with areas of low perfusion, but its sensitivity and specificity is similar to that of time-flight magnetic resonance angiography(MRA) for the diagnosis of large vessel occlusion.DWI volume and FVH-DWI mismatch in acute stroke patients might be useful for predicting functional outcome after stroke[10]. It was thus hypothesized that FVH sign could be an important and convenient imaging manifestation reflecting the under-perfusion of brain tissue in patients with cerebral infarction with LVO. . In this study, a randomised controlled approach was adopted to assess the risk and prognosis of endovascular treatment by using the "FVH-DWI mismatch" to determine the presence of an ischemic penumbra and collateral circulation in patients, with the aim of establishing a simple evaluation method based on the indirect evaluation of collateral circulation on MR to screen patients who underwent thrombolysis at 6 to 24 hours overtime. It may be similar to the perfuse evaluation system, but is more easily replicable.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endovascular Thrombectomy
Keywords
select patients, endovascular thrombectomy, magnetic resonance imaging, CT/MR perfusion, FVH-DWI mismatch

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The study's emergency green channel team screened patients at 6-24 hours of onset for possible LVO based on NCCT scan and NIHSS score of ≥6 as the proposed cohort. Patients who met the entry criteria were then randomized 1:1 by the arriving stroke specialist into two groups 1 and 2 as follows, with the order of randomization being the responsibility of an independent investigator. The MRI group performed DWI, FLAIRE, and 3D-TOF sequences. The Control group performed perfusion sequences(CTP or PWI) and processed them with F-Stroke stroke software (Neuroblem Technology)
Masking
None (Open Label)
Masking Description
Emergency department physicians were not aware of the experimental and allocation. The physician responsible for the assessment and the patients are aware of the allocation; the attending physician is aware of the experimental and allocation. Two neurointerventional specialists were assigned to the experiment. Two neurointerventionalists evaluate the procedure based on the imagings provided by the respective group and decide whether to proceed. If there is a disagreement, it will be decided by a third senior neurointerventional specialist. The committee responsible for assessing primary and secondary outcomes and the imaging center specialists were not informed of the subgroup results. Outcome analysis was performed by an independent statistician, and results were reported directly to the data and safety regulatory committee, the investigator being aware of the results at this time.
Allocation
Randomized
Enrollment
214 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
MR/CT perfusion group
Arm Type
Other
Arm Description
MRI group consisted of patients who underwent DWI, FLAIRE, T1, T2, and MRA sequences.After randomization, the attending physician determined surgical treatment based on the imaging results.
Arm Title
MRI group
Arm Type
Other
Arm Description
The perfusion sequence was examined by the Control Group, and the F-stroke Stroke software (Brainseal Intelligent Technology) was used for data processing.After randomization, the attending physician determined surgical treatment based on the imaging results.
Intervention Type
Procedure
Intervention Name(s)
Endovascular therapy
Intervention Description
Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging. Endovascular therapy includes any one or more of the following: Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.Remedial measures after failed thrombectomy are permitted by pharmacologic arterial thrombolysis or intravenous infusion of antiplatelet drugs, such as tirofiban or rt-PA
Intervention Type
Drug
Intervention Name(s)
Drug
Other Intervention Name(s)
Drug conservative therapy
Intervention Description
Drug conservative therapy could be uesd in patients who with no indication of surgery
Primary Outcome Measure Information:
Title
Functionally independent outcome in all enrolled patients
Description
defined as patients with a mRS Score of 0-2 at 90 days (mRS 90d(Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, and 6 death,) of a randomized group of modified intention-to-treat (mITT) patients (defined as patients with acute macrovascular occlusions treated optimally with endovascular or pharmacologic therapy) at 90 days (with an assessment time window of ±14 days) and analyzed for noninferiority.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Modified Rankin scale scores at 90 days
Description
(mRS 90d(Scores on the modified Rankin scale range from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, and 6 death,) of a randomized group of modified intention-to-treat (mITT) patients (defined as patients with acute macrovascular occlusions treated optimally with endovascular or pharmacologic therapy) at 90 days (with an assessment time window of ±14 days) and analyzed for noninferiority.
Time Frame
90 days
Title
Successful reperfusion after endovascular treatment
Description
extended Thrombolysis in Cerebral Infarction (eTICI) score of 2b, 2c or 3.
Time Frame
immediately the surgeon thought the thrombectomy completed and performed a second cerebral angiography
Title
Recanalization rate
Description
Number of subjects who achieved successful reperfusion/total number of subjects who received endovascular treatment, confirmed by MRA, CTA, or digital subtraction angiography (DSA).
Time Frame
72 hours
Title
Final infarct volume
Description
change from baseline in the infarct volume as calculated by CBV or DWI.
Time Frame
72hours
Title
NIHSS score
Description
scores range from 0 to 42, with higher scores indicating a more severe deficit.
Time Frame
24 hours、72hour sand 7 days postoperatively
Title
Quality of life assessment at 90 days
Description
European Five Dimensions and Five Levels Scale (EQ-5D-5L) scores (range, -0.39 [worst] to 1.00 [best]); Barthel Index scores at 90 days (range, 0 [severe disability] to 100 [no disability]).
Time Frame
90 days
Title
mortality
Description
mortality of all-cause.
Time Frame
90 days
Title
symptomatic intracranial hemorrhage
Description
the presence of extravascular blood in the cranium that was associated with an increase in the NIHSS score of ≥4 points or death and was judged to be the predominant cause of neurologic deterioration.
Time Frame
48 hours
Title
FVH-ASPECT score
Description
FVH-ASPECTS: 0-7, with 0 indicating absence of FVH and 7 suggesting prominent FVH
Time Frame
24 hours、72hour sand 7 days postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients over 18 years of old; Patients with acute anterior circulation ischemic stroke 6-24h after onset and NIHSS score ≥6 and RACE score ≥5 score at 6-24 hours of onset; No intracranial hemorrhage confirmed by cranial CT and CT ASPECTS score ≥ 6; The Modified Rankin Scale (mRS) before the onset of the disease was 0-2; All patients' legal representatives have signed the informed consent form; Pre-survival period 6 months or more. Exclusion Criteria: 1. Active hemorrhage or preexisting tendency to hemorrhage CT shows hypointense areas exceeding 1/3 of the middle cerebral artery supply area, with significant midline structural displacement of cerebral edema Rapid neurological improvement, NIHSS score less than 6, or evidence of spontaneous revascularization Signs and symptoms typical of posterior circulation stroke, such as vertigo, nystagmus, choking, swallowing disorder, ataxia, and gaze to the affected side A stroke attack with epilepsy that prevents an accurate NIHSS score from being obtained. A platelet count of less than 100 x 10^9 /L Hereditary or acquired bleeding tendency, coagulation factor deficiency, recent anticoagulant medication (INR>3 or PPT more than 3 times normal) Presence of signs of cardiac, hepatic or renal failure Baseline blood glucose <50mg/dL (2.78mmol) or >400mg/dL (22.20mmol) Uncontrolled hypertension (SBP >185mmHg; DBP >110mmHg) Expected survival less than 90 days. Pregnancy. Chronic obstructive pulmonary disease, inflammation of the lungs, pleural effusion, ARDS, irregular breathing and other pulmonary diseases requiring emergency treatment. Patients with unstable vital signs (heart rate ≤ 50bpm or ≥ 120bpm, oxygen saturation less than ≤ 90%. R ≥ 30bpm or ≤ 10bpm. Patients who are unable to complete the 90-day follow-up A history of severe allergy to contrast media The presence of any other condition that is not suitable for endovascular treatment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ming Wei, doctorate
Phone
13502182903
Email
drweiming@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ming Wei, doctorate
Organizational Affiliation
Tianjin Huanhu Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
TianJinHH
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300222
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ming Wei, doctorate
Phone
13502182903
Email
drweiming@163.com
First Name & Middle Initial & Last Name & Degree
Ming Wei, doctorate

12. IPD Sharing Statement

Learn more about this trial

MR Imaging Selection for Endovascular Treatment in Acute Ischemic Stroke at 6 to 24 Hours

We'll reach out to this number within 24 hrs